Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMPBCLA)

• Drug Name: CY-9652 Drug Info
• Synonyms: Integrin antagonists, Cytel

Indication

Disease Entry	ICD 11	Status	REF
Inflammation	1A00-CA43.1	Terminated	[1]

• Cross-matching ID: TTD Drug ID: DMPBCLA

Molecule-Related Drug Atlas

Drug(s) Targeting Integrin alpha-4/beta-1 (ITGA4/B1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
AJM-300	DM5K6J4	Crohn disease	DD70	Phase 3	[3]
TRK-170	DM13G5R	Inflammatory bowel disease	DD72	Phase 2	[4]
R411	DMP7J0S	Asthma	CA23	Phase 2	[5]
CDP323	DMXYLTI	Multiple sclerosis	8A40	Phase 2	[6]
Firategrast	DMW2QYT	Multiple sclerosis	8A40	Phase 2	[7]
HMR-1031	DM695QT	Arthritis	FA20	Phase 1	[8]
BIIB107	DMIA57S	Multiple sclerosis	8A40	Phase 1	[9]
TR-14035	DMWD39E	Multiple sclerosis	8A40	Discontinued in Phase 1	[10]
TCS2314	DMBVYQR	Discovery agent	N.A.	Investigative	[11]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Integrin alpha-4/beta-1 (ITGA4/B1)	TT6S84X	ITA4_HUMAN-ITB1_HUMAN	Antagonist	[2]

References

• [1] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800006649)
• [2] US patent application no. 2010,0278,784, Methods and compositions for treating skin conditions.
• [3] Oral treatment with a novel small molecule alpha 4 integrin antagonist, AJM300, prevents the development of experimental colitis in mice. J Crohns Colitis. 2013 Dec;7(11):e533-42.
• [4] Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
• [5] Integrins as therapeutic targets: lessons and opportunities. Nat Rev Drug Discov. 2010 Oct;9(10):804-20.
• [6] Pharmacodynamic consequences of administration of VLA-4 antagonist CDP323 to multiple sclerosis subjects: a randomized, double-blind phase 1/2 study.PLoS One.2013;8(3):e58438.
• [7] Firategrast for relapsing remitting multiple sclerosis: a phase 2, randomised, double-blind, placebo-controlled trial.Lancet Neurol.2012 Feb;11(2):131-9.
• [8] Pharmacoscintigraphic comparison of HMR 1031, a VLA-4 antagonist, in healthy volunteers following delivery via a nebulizer and a dry powder inhaler. Am J Ther. 2004 Mar-Apr;11(2):103-13.
• [9] ClinicalTrials.gov (NCT04593121) A Phase 1, Randomized, Blinded, Placebo-Controlled, Single- and Multiple-Ascending-Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB107 in Healthy Adult Participants. U.S.National Institutes of Health.
• [10] Pharmacokinetics and metabolism of TR-14035, a novel antagonist of a4ss1/a4ss7 integrin mediated cell adhesion, in rat and dog. Xenobiotica. 2005 Apr;35(4):373-89.
• [11] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2580).